BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3581106)

  • 1. Treatment of refractory non-Hodgkin's lymphomas of unfavorable histology with teniposide, cytarabine, and cisplatin.
    Tseng A; Jacobs C; Coleman CN; Horning SJ; Lewis BJ; Rosenberg SA
    Cancer Treat Rep; 1987 Jun; 71(6):659-60. PubMed ID: 3581106
    [No Abstract]   [Full Text] [Related]  

  • 2. Cytarabine, cisplatin, and etoposide chemotherapy for refractory non-Hodgkin's lymphoma.
    O'Donnell MR; Forman SJ; Levine AM; Territo M; Farbstein MJ; Fahey JL; Gill P; Lazar G; Nademanee A; Neely S
    Cancer Treat Rep; 1987 Feb; 71(2):187-9. PubMed ID: 3802114
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of advanced refractory lymphomas with a combination of carmustine, bleomycin, teniposide, dexamethasone, and cisplatin (the BBVDD regimen). An ECOG pilot study.
    Spiers AS; Weens JH; Rowe JM; Smith TJ; Horton J; Gordon LI; Glick JH
    Am J Clin Oncol; 1991 Dec; 14(6):519-25. PubMed ID: 1720279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etoposide and mitoguazone in refractory or recurrent non-Hodgkin's lymphomas of the unfavorable histologic subtypes.
    Winter JN; Gordon LI; Hauck WW; Variakojis D
    Cancer Treat Rep; 1986 Oct; 70(10):1243-4. PubMed ID: 3756945
    [No Abstract]   [Full Text] [Related]  

  • 5. DHAP treatment: results of 18 patients with refractory or recurrent non Hodgkin's lymphoma.
    Martelli M; Cimino G; Gastaldi R; Mantovani L; Sgadari C; Amadori S; Guglielmi C
    Haematologica; 1990; 75(2):194-5. PubMed ID: 2358209
    [No Abstract]   [Full Text] [Related]  

  • 6. ESHAP chemotherapy for relapsed/refractory non-Hodgkin's lymphoma.
    Sweetenham JW; Johnson PW
    J Clin Oncol; 1994 Dec; 12(12):2766. PubMed ID: 7989954
    [No Abstract]   [Full Text] [Related]  

  • 7. Rituximab plus ASHAP for the treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma: a single-centre study of 20 patients.
    Aydin S; Dührsen U; Nückel H
    Ann Hematol; 2007 Apr; 86(4):271-6. PubMed ID: 17216473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Salvage combination chemotherapy with cisplatinum, etoposide and bleomycin in refractory non-Hodgkin's lymphomas.
    Comella P; Abate G; Di Finizio G; Fiore M; Zarrilli D
    J Chemother; 1989 Jul; 1(4 Suppl):1262-3. PubMed ID: 16312858
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of resistant non-Hodgkin's lymphomas with cisplatin, etoposide, vindesine, methotrexate with leucovorin rescue. Greek Lymphoma Research Group.
    Chemioterapia; 1987 Jun; 6(2 Suppl):721-3. PubMed ID: 3509941
    [No Abstract]   [Full Text] [Related]  

  • 10. [Preliminary study on DHAP regimen for patients with relapsed and refractory non-Hodgkin's lymphoma].
    Li YH; Jiang WQ; Huang HQ; Zhang L; Liu DG; Xu RH; Zhou ZM; Sun XF; Lin TY; Xu GC; He YJ; Guang ZZ
    Ai Zheng; 2002 Aug; 21(8):900-2. PubMed ID: 12478903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Late recurrences in non-Hodgkin's lymphomas with unfavorable histology].
    Pereira A; Montserrat E; Nomdedeu B; Urbano Ispizua A; Rozman C
    Sangre (Barc); 1986; 31(5):582-6. PubMed ID: 3810413
    [No Abstract]   [Full Text] [Related]  

  • 12. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Mey UJ; Orlopp KS; Flieger D; Strehl JW; Ho AD; Hensel M; Bopp C; Gorschlüter M; Wilhelm M; Birkmann J; Kaiser U; Neubauer A; Florschütz A; Rabe C; Hahn C; Glasmacher AG; Schmidt-Wolf IG
    Cancer Invest; 2006 Oct; 24(6):593-600. PubMed ID: 16982464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Use of dexamethasone in treatment of high- and low-grade non-Hodgkin's lymphoma].
    Alekseeva IuA; Zaritskiĭ AIu; Medvedeva NV; Mikhaĭlova NB; Zubarovskaia LS; Afanas'ev BV
    Vopr Onkol; 2004; 50(6):726-8. PubMed ID: 15755073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose infusional ifosfamide, etoposide plus methylprednisolone followed by dexamethasone, high-dose ara-C and cisplatinum and autologous stem cell transplantation for refractory or relapsed aggressive non-Hodgkin's lymphoma.
    Salar A; Martino R; Perea G; Ribera JM; López-Guillermo A; Guardia R; Escoda L; Altés A; Sierra J; Montserrat E
    Haematologica; 2002 Oct; 87(10):1028-35. PubMed ID: 12368156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topotecan, Ara-C, cisplatin and prednisolone (Toposhap) for patients with refractory and relapsing lymphomas: Results of a phase II trial.
    Dantas AA; Manhani AR; Coutinho F; Del Giglio A
    Acta Haematol; 2006; 116(4):275-8. PubMed ID: 17119330
    [No Abstract]   [Full Text] [Related]  

  • 17. [High-dose chemotherapy supported by peripheral blood stem cells to treat intermediate--and high-grade non-Hodgkin's lymphomas].
    Ji Y; Ji S; Ju X
    Zhonghua Zhong Liu Za Zhi; 1996 Nov; 18(6):471-5. PubMed ID: 9387307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophosphamide, epirubicin, vincristine, and prednisone (CEOP) in the treatment of advanced stage non-Hodgkin's lymphomas with poor histology.
    Comella P; Abate G; Fiore M; Di Finizio G; Zarrilli D
    J Chemother; 1989 Jul; 1(4 Suppl):1257-8. PubMed ID: 16312856
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of refractory Hodgkin's disease with teniposide, cisplatin, hexamethylmelamine, and prednisolone: cancer and leukemia group B trial 8171.
    Budman DR; Anderson J; Obrecht JP; Canellos GP; Creaven P; Norton L; Gottlieb A
    Cancer Treat Rep; 1985 Jun; 69(6):719-20. PubMed ID: 3926312
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
    Klumpp TR; Mangan KF; Glenn LD; Malaspina DR; Cropper T; Mullaney M; Macdonald JS
    Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.